Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pumping every 2 hours Clear all
Recruiting Not applicable Interventional

Pumping to Up Maternal Milk Production for Preterms

NCT06673160
View directory record Official record
Conditions
Breastfeeding, Breastmilk Expression
Interventions
Pumping every 2 hours, breast pumping every 3 hours
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 28 Days
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

NCT05121038
View directory record Official record
Conditions
Colon Cancer, Pancreas Cancer, Digestive Cancer
Interventions
CEND-1, Panitumumab, Folfirinox
Drug
Lead sponsor
Anup Kasi
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

NCT00525785
View directory record Official record
Conditions
Stomach Cancer, Gastric Cancer
Interventions
5-Fluorouracil, Folinic Acid, Oxaliplatin, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Regulation of Reproductive Hormones in Adult Men

NCT00392457
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions
ketoconazole, gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

NCT02996474
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Pembrolizumab, Decitabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

NCT02432456
View directory record Official record
Conditions
Wounds and Injuries, Rib Fractures
Interventions
Ketamine, Placebo, Intercostal Nerve Block, Acetaminophen, Ibuprofen, Pantoprazole, Methocarbamol, Opioid
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

NCT00819780
View directory record Official record
Conditions
Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
Interventions
Panitumumab, Bevacizumab, mFOLFOX6
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 5, 2026, 2:05 AM EDT
Terminated Phase 3 Interventional Results available

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

NCT01189227
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Postoperative chemotherapy, Perioperative chemotherapy
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
283
States / cities
Antioch, California • Duarte, California • Fremont, California + 210 more
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

NCT01405391
View directory record Official record
Conditions
Major Advanced Solid Tumors Other Than Colorectal
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

NCT01980095
View directory record Official record
Conditions
Dyspepsia, Helicobacter Pylori Infection
Interventions
RHB-105, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Anaheim, California • Chino, California • Jupiter, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

NCT00002745
View directory record Official record
Conditions
Lymphoma
Interventions
aminocamptothecin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Minneapolis, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Continuous Subpleural Infusion of Bupivacaine

NCT01566838
View directory record Official record
Conditions
Postoperative Pain
Interventions
Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

NCT00201812
View directory record Official record
Conditions
Tumors
Interventions
Etanercept, Docetaxel, Dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Pain Management for Pectus Excavatum Repair

NCT00413582
View directory record Official record
Conditions
Postoperative Pain
Interventions
Epidural Analgesia, Patient-Controlled IV Analgesia
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2012 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

NCT00308516
View directory record Official record
Conditions
Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Radiation Therapy, Oxaliplatin, Leucovorin
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
14
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum

NCT05271136
View directory record Official record
Conditions
Fine Lines, Wrinkle, Photoaging
Interventions
Anti-aging Serum, Facial Moisturizer, Cleansing Lotion, Sunscreen
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
30 Years to 60 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 5, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

NCT03203525
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
Interventions
Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pegylated Liposomal Doxorubicin Hydrochloride, Temsirolimus, Tumor Treating Fields Therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

NCT07468175
View directory record Official record
Conditions
Hyperpigmentation, Dark Spots
Interventions
Cosmetic dark spot corrector serum
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

NCT00591123
View directory record Official record
Conditions
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
Interventions
FOLFOX, 5-FU, Erlotinib
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 5, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Allo HSCT for High Risk Hemoglobinopathies

NCT06872333
View directory record Official record
Conditions
Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions
Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil)
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 5, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

NCT00762476
View directory record Official record
Conditions
Common Cold
Interventions
3804-250A, 3804-291
Drug
Lead sponsor
The Dial Corporation
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Paramus, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Sep 5, 2026, 2:05 AM EDT